skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Preliminary results following the use of a fixed combination of timolol–brimonidine in patients with ocular hypertension and primary open-angle glaucoma

Rapid Communication

(3404) Views  (727) Full article downloads

Authors: Dimitris Papaconstantinou, Ilias Georgalas, Nikolaos Kourtis, Christos Pitsas, et al.

Published Date March 2009 Volume 2009:3 Pages 227 - 230
DOI: http://dx.doi.org/10.2147/OPTH.S5053

Dimitris Papaconstantinou1, Ilias Georgalas2, Nikolaos Kourtis1, Christos Pitsas1, Efthimios Karmiris1, Chrysanthi Koutsandrea1, Ioannis Ladas1, Gerasimos Georgopoulos1

1Department of Ophthalmology, “G Gennimatas” Hospital of Athens, University of Athens, Athens, Greece; 2Department of Ophthalmology, “G Gennimatas” Hospital of Athens, NHS, Athens, Greece

Purpose: The purpose of this prospective study was to evaluate the efficacy in intraocular pressure (IOP) control and the tolerance of a topically administered fixed combination of timolol–brimonidine in 50 patients with ocular hypertension and primary open-angle glaucoma.

Methods: After determining a baseline IOP, the fixed combination timolol–brimonidine was used twice daily for two months, while IOP, ophthalmic signs, and/or symptoms were monitored.

Results: The mean IOP value was decreased from 23.09 mm Hg (±1.98 SD) to 17.46 mm Hg (±1.47 SD) during the 1st month (paired Student’s t test = 9.88 και p < 0.001), and to 17.51 mm Hg (±1.43 SD) in the 2nd month. Between the 1st and 2nd month, no statistical difference was observed (paired Student’s t test = 0.02 και p < 0.1). In 8% of the patients during the 1st month and 10% of patients in the 2nd month, some ophthalmic signs were observed, while only mild ophthalmic symptoms were reported in 6% and 8% of the patients, respectively.

Conclusions: In conclusion, the fixed combination of timolol–brimonidine has a satisfactory IOP-lowering effect without any serious side effects due to the topical use.

Keywords: fixed combination 0.2% brimonidine–0.5% timolol, ocular hypertension, primary open-angle glaucoma




 

Other articles by Dr Ilias Georgalas

A case of subretinal neovascularization treated with intravitreal ranibizumab in a patient with idiopathic juxtafoveal retinal telangiectasis
Acquired color vision and visual field defects in patients with ocular hypertension and early glaucoma
Angioid streaks, clinical course, complications, and current therapeutic management
Contemporary aspects in the prognosis of traumatic hyphemas
Cytomegalovirus retinitis presenting as vasculitis in a patient with Wegener’s granulomatosis
Foveal thickness after phacoemulsification as measured by optical coherence tomography
Lens-induced glaucoma in the elderly
Nd: YAG capsulotomy for posterior capsule opacification after combined clear corneal phacoemulsification and vitrectomy
Photodynamic therapy of choroidal neovascularization with enlargement of the spot size to include the feeding complex
Severe hypotony and filtering bleb leak after intravitreal injection of ranibizumab


Readers of this article also read:

Acquired color vision and visual field defects in patients with ocular hypertension and early glaucoma
Evidence-based decision-making within the context of globalization: A “Why–What–How” for leaders and managers of health care organizations
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
The utility of an electronic adherence assessment device in type 2 diabetes mellitus: a pilot study of single medication
Evaluation of alcaftadine 0.25% ophthalmic solution in acute allergic conjunctivitis at 15 minutes and 16 hours after instillation versus placebo and olopatadine 0.1%
Living with diabetes: quality of care and quality of life
Twelve-week, randomized, multicenter study comparing a fixed combination of brimonidine-timolol with timolol as therapy adjunctive to latanoprost
A case of recurrent bloody tears
Erratum
Erratum